Fulcrum Therapeutics Q1 net loss widens on higher expenses

Fulcrum Therapeutics

27/04/2026 12:08

Overview

US rare disease drugmaker's Q1 net loss widened on higher R&D and G&A expenses

Company ended Q1 with $333.3 mln in cash, expects runway into 2029

Outlook

Fulcrum expects current cash to fund operations into 2029

Result Drivers

INCREASED OPERATING EXPENSES - Higher R&D and G&A costs, mainly from increased employee compensation and professional services, contributed to a wider net loss

Company press release: ID:nGNX1gvFxM

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Net Income
-$18.89 mln
Q1 Operating Income
Beat
-$22.19 mln
-$23.02 mln (11 Analysts)
Q1 Basic EPS
-$0.25
Q1 Operating Expenses
$22.19 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 1 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Fulcrum Therapeutics Inc is $23.00, about 193.4% above its April 24 closing price of $7.84

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)